NCT01614184撤回1 期
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Operable Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Sentinel Lymph node (SLN) detection
研究概览
简要总结
The study goal is to develop a new method of intraoperative lymphatic mapping with fluorescent contrast agents to improve the outcome of therapeutic breast cancer surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patient
- •Ability to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.
- •Between 18 and 90 years of age.
- •Have been diagnosed with invasive adenocarcinoma, or high-grade ductal carcinoma in-situ. If a core or open biopsy is done, it must demonstrate invasive adenocarcinoma. If only a FNA is done, it must be positive and accompanied by a positive clinical breast examination and ultrasound or mammography. The tumor must be operable.
- •Clinically negative lymph nodes.
- •Must have had a bilateral mammogram within a year of enrollment.
- •The interval between the initial cytologic or histologic diagnosis of breast cancer and enrollment must be no more than 60 days.
- •ECOG performance status 0-1
- •Patients in whom the diagnosis of breast cancer has been obtained utilizing fine needle aspiration cytology or core needle biopsy are preferred. However, patients who are diagnosed by open biopsy procedures are eligible.
- •Patients with prior excisional biopsy or lumpectomy are eligible for entry.
- •Patients with prior non-breast malignancies are eligible if they have been disease free for 5 years before enrollment. Patients with squamous or basal cell carcinoma of the skin that has been effectively treated, carcinoma in situ of the cervix that has been treated by operation only, or LCIS of the ipsilateral or contralateral breast treated by surgery only are eligible, even if these conditions were diagnosed within 5 years before enrollment onto this study.
排除标准
- •Male patient
- •Ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude. (Tethering or dimpling of the skin or nipple inversion should not be interpreted as skin infiltration. Patients with these latter to conditions are eligible.)
- •One or more ipsilateral axillary lymph nodes that are positive for tumor on clinical examination.
- •Bilateral malignancy or a mass in the opposite breast that is suspicious for malignancy, unless a biopsy proves that the mass is not malignant.
- •Previous removal of any ipsilateral axillary lymph node.
- •Diffuse tumors or multiple malignant tumors in different quadrants of the breast.
- •Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes. Patients with these conditions are considered ineligible unless there is biopsy evidence that these are not involved with tumor.
- •Patients with any prior breast malignancy other than LCIS.
- •Prior treatment for this breast cancer including irradiation, chemotherapy, immunotherapy, and/or hormonal therapy.
- •Allergy to radiocolloid or fluorescein.
- •Inability to localize SLN drainage basins via lymphatic mapping. (e.g., no basin found which emits gamma-radiation after injection with technetium -99)
- •Organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that might preclude participation in the protocol, or be exacerbated by therapy.
- •Breast cancer related operative procedures not corresponding to criteria described in the protocol.
- •Primary or secondary immune deficiencies or known significant autoimmune disease which would pose a risk to the participant based on the physician's judgment.
- •History of organ transplantation.
- •Pregnant or lactating women.
- •Participation in concurrent experimental protocols or alternative therapies that might confound the analysis of this trial.
- •Nonmalignant systemic disease (e.g., cardiovascular, renal, hepatic, etc.) that precludes a patient from being subjected to any of the treatment options or that would prevent prolonged follow-up based on the physician's judgment.
研究组 & 干预措施
All patients
Experimental
All patients enrolled in study.
干预措施: Fluorescein (Drug)
结局指标
主要结局
Sentinel Lymph node (SLN) detection
时间窗: 36 months
Ability of peri-areolar or peri-tumoral fluorescein to detect SLNs in patients with operable breast cancer.
次要结局
- Correlation between two radiation intensities(36 months)
- Fluorescence detection(36 months)
- Number of patients with adverse events(36 months)
- Fluorescence detection after processing(36 months)
- Correlation between intensity and metastasis(36 months)
研究者
相似试验
已完成
1 期
Fluorescent Dyes for Lymph Node MappingBreast CancerNCT01095913M.D. Anderson Cancer Center30
已完成
不适用
Intraoperative Evaluation of Axillary LymphaticsLymphedemaSurgeryBreast CancerNCT05094102University of Wisconsin, Madison9
撤回
不适用
Intraoperative Fluorescence Angiography in Debridement of Open FracturesIntraoperative Fluorescence AngiographyNCT05006313Vanderbilt University Medical Center20
撤回
不适用
Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung CancerLung CancerNCT02423148Dana-Farber Cancer Institute
已完成
1 期
NIR-Guided Sentinel Lymph-Node Mapping for Esophageal CancerEsophageal CancerNCT01808417Dana-Farber Cancer Institute10